Loading
Traverse Biotech
Traverse Biotech is a New York company that licenses immunotherapies already tested outside the United States and develops them further. Its lead product, TB-Bs1, is an antibody that links T cells to cancer cells carrying the protein ROR2.
Also called: TRAVERSE BIOTECH II INCTraverse Biotechnology
Overview
Traverse Biotech, of New York City, describes itself as an immunotherapy company that acquires products built on clinically validated platforms under a risk-sharing model with the licensing partner. Its pipeline page names TB-Bs1, a CD3 by ROR2 DuoBody bispecific antibody for ROR2-positive solid tumours, as its lead product, alongside an innate immunity programme, an antibody-drug conjugate in an undisclosed indication and an in situ immunotherapy platform. In fiscal year 2026 the National Cancer Institute funded its SBIR project on a uPAR-targeting antibody-drug conjugate for pancreatic adenocarcinoma (1R43CA309866-01, USD 399,896).
Headquarters
New York, NY, US
Scorecard
All companies#694of 1706 companies, score 4
- targets +2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR Phase I (R43) award 1R43CA309866-01: Development of a uPAR-Targeting Antibody-Drug Conjugate (ADC) for Pancreatic Adenocarcinoma | 2026 | $400K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1PreclinicalBispecific antibody (T-cell engager)
TB-Bs1 is a bispecific antibody from Traverse Biotech that links T cells to tumour cells carrying ROR2, being developed for solid tumours.
Notes
- Read on traversebiotech.com (home and pipeline pages) and the NIH RePORTER record on 4 November 2026. The site does not say whether its undisclosed antibody-drug conjugate is the uPAR programme. No ROR2 target record exists in the corpus.
Connected
7Similar pages
- TreatmentGlyTR1
Shares CD3, T-cell engagers (bispecific).
- CompanyAdaptin Bio
Shares CD3, T-cell engagers (bispecific).
- CompanyJanux Therapeutics
Shares CD3, T-cell engagers (bispecific).
- PersonElias Jabbour
Shares CD3, T-cell engagers (bispecific), Antibody-drug conjugate (ADC).
- TreatmentMipletamig
Shares CD3, T-cell engagers (bispecific).
- TreatmentAPTN-101
Shares CD3, T-cell engagers (bispecific).
- CompanyVitruviae
Shares CD3, T-cell engagers (bispecific).
- CompanyHarpoon Therapeutics
Shares CD3, T-cell engagers (bispecific).
cancers
fronts
technologies
targets
drugs
PreclinicalBispecific antibody (T-cell engager)
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
traversebiotech.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/